Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vinge, E.
Right arrow Articles by Andersson, K. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vinge, E.
Right arrow Articles by Andersson, K. E.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Brain Aneurysm

Stroke, Vol 19, 644-647, Copyright © 1988 by American Heart Association


ARTICLES

Thromboxane B2 levels in serum during continuous administration of nimodipine to patients with aneurysmal subarachnoid hemorrhage

E Vinge, L Brandt, B Ljunggren and KE Andersson
Department of Clinical Pharmacology, University Hospital, Lund, Sweden.

Twenty-four patients with subarachnoid hemorrhage due to rupture of a supratentorial aneurysm underwent surgery within 72 hours after subarachnoid hemorrhage. Immediately after clipping of the aneurysm the patients were treated with intravenous nimodipine for at least 7 days and then received the drug orally for another week. Nine patients had a documented or probable intake of aspirin or other nonsteroid anti- inflammatory drug during the days preceding admission. In all patients there was a gradual increase in serum thromboxane B2 concentration from low to normal levels during the treatment period, the increase being most pronounced in patients with prior nonsteroid anti-inflammatory drug intake. Thromboxane B2 concentrations were similar to those of four control patients not receiving nimodipine. In three patients who developed delayed ischemic dysfunction despite "therapeutic" nimodipine plasma concentrations, the thromboxane B2 levels were low or normal. Our present results do not support the idea that nimodipine exerts an effect on platelet function in patients with aneurysmal subarachnoid hemorrhage.


This article has been cited by other articles:


Home page
StrokeHome page
S. M. Dorhout Mees, G. J.E. Rinkel, J. W. Hop, A. Algra, and J. van Gijn
Antiplatelet Therapy in Aneurysmal Subarachnoid Hemorrhage: A Systematic Review
Stroke, September 1, 2003; 34(9): 2285 - 2289.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
J. van Gijn and G. J. E. Rinkel
Subarachnoid haemorrhage: diagnosis, causes and management
Brain, February 1, 2001; 124(2): 249 - 278.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
J. W. Hop, G. J. E. Rinkel, A. Algra, J. W. B. van der Sprenkel, and J. van Gijn
Randomized pilot trial of postoperative aspirin in subarachnoid hemorrhage
Neurology, February 22, 2000; 54(4): 872 - 878.
[Abstract] [Full Text] [PDF]